The UK and US have secured a landmark trade agreement that will preserve no levies on British drug exports entering the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost spending on pharmaceuticals through the National Health Service (NHS). This pledge ensures that duties on these key products will be held at zero for a timeframe of three years.
This deal follows recent threats to significantly raise import taxes on patented drug imports, with figures discussed as high as double the cost.
"This deal between the United Kingdom strengthens the international landscape for cutting-edge drugs and brings much-needed balance to transatlantic medicine commerce," a release declared.
Economic Impact
Drugs constitute one of the UK's most significant goods shipped to the United States, which is clearly the biggest market for large UK drugmakers.
Trade data reveal that in the year leading up to September, the UK shipped medicines worth billions to the US. This value made up a significant portion of total UK exports in that timeframe.
"This deal safeguards employment, stimulates capital expenditure and facilitates the UK to become a global hub for biotech and pharma," a government official stated.
Detailed UK Commitments
The deal entails several key pledges from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to double total public funding on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount manufacturers must return to the NHS to control costs will be limited at 15%. Previously, refunds exceeded 20%.
Broader Context
This agreement comes amid a protracted row between the drug companies and the UK government over drug pricing and NHS adoption.
This friction were intensified by claims that US customers were paying significantly more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been halted or cancelled, while major funding commitments have been directed toward American operations.
The Science Minister stated that the NHS had to invest a greater share on medicines, noting that its spending on drugs had decreased as a proportion of its resources over the previous ten-year period.
